MX2019000882A - Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo. - Google Patents

Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.

Info

Publication number
MX2019000882A
MX2019000882A MX2019000882A MX2019000882A MX2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A MX 2019000882 A MX2019000882 A MX 2019000882A
Authority
MX
Mexico
Prior art keywords
raav
recombinant adeno
associated viral
vector
recovery methods
Prior art date
Application number
MX2019000882A
Other languages
English (en)
Inventor
Fraser Wright John
Qu Guang
Oh Younghoon
Wang Yuhuan
Zhang Haibo
Duncan Laura
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of MX2019000882A publication Critical patent/MX2019000882A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan métodos para producir partículas de vectores de virus adenoasociados recombinantes (rAAV) con una alta recuperación o título alto. También se proporcionan métodos para concentrar vectores de rAAV a una alta concentración, por ejemplo, hasta por 5E+13 (5x101313) genomas de vector por mililitro (Vg/mL) con pocos o ningún agregado de rAAV.
MX2019000882A 2016-07-21 2017-07-21 Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo. MX2019000882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365312P 2016-07-21 2016-07-21
PCT/US2017/043291 WO2018017956A2 (en) 2016-07-21 2017-07-21 Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby

Publications (1)

Publication Number Publication Date
MX2019000882A true MX2019000882A (es) 2019-08-12

Family

ID=60992897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000882A MX2019000882A (es) 2016-07-21 2017-07-21 Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.

Country Status (18)

Country Link
US (1) US20190284576A1 (es)
EP (1) EP3488007B1 (es)
JP (1) JP7153009B2 (es)
KR (2) KR20190045174A (es)
CN (1) CN109790549A (es)
AU (1) AU2017299779B2 (es)
BR (1) BR112019001146A2 (es)
CA (1) CA3031095A1 (es)
DK (1) DK3488007T3 (es)
ES (1) ES2972859T3 (es)
FI (1) FI3488007T3 (es)
IL (2) IL301963A (es)
MX (1) MX2019000882A (es)
MY (1) MY194198A (es)
PT (1) PT3488007T (es)
RU (1) RU2768045C2 (es)
SG (1) SG11201900366QA (es)
WO (1) WO2018017956A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3356390T (pt) 2015-09-28 2021-04-21 Univ Florida Métodos e composições para vetores virais que se evadem a anticorpos
CA3034527A1 (en) 2016-08-23 2018-03-01 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
WO2020210600A1 (en) * 2019-04-11 2020-10-15 Regenxbio Inc. Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
BR112022006530A2 (pt) 2019-10-17 2022-07-05 Stridebio Inc Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Preparations and methods for the treatment of hearing impairment that is not related to age in humans
WO2023085382A1 (ja) * 2021-11-12 2023-05-19 Ａｇｃ株式会社 ウイルスの精製方法
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647477T3 (es) 2004-06-01 2017-12-21 Genzyme Corporation Composiciones y métodos para prevenir la agregación del vector AAV
TW200634145A (en) 2005-01-25 2006-10-01 Wyeth Res Ireland Ltd Shear protectants in harvest microfiltration
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US20110165645A1 (en) * 2008-02-12 2011-07-07 Yelin Xiong Methods Using Ion Exchange and Gel Filtration Chromatography for Poxvirus Purification
CA2738022A1 (en) * 2008-09-24 2010-04-01 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
WO2012057363A1 (ja) * 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
PT2970948T (pt) * 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa Métodos de purificação de arn
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step

Also Published As

Publication number Publication date
EP3488007A2 (en) 2019-05-29
WO2018017956A3 (en) 2018-03-08
JP7153009B2 (ja) 2022-10-13
IL301963A (en) 2023-06-01
RU2768045C2 (ru) 2022-03-23
MY194198A (en) 2022-11-21
RU2019104759A (ru) 2020-08-21
IL264270A (en) 2019-02-28
BR112019001146A2 (pt) 2019-04-30
CA3031095A1 (en) 2018-01-25
EP3488007B1 (en) 2023-12-20
WO2018017956A2 (en) 2018-01-25
EP3488007A4 (en) 2020-01-01
RU2019104759A3 (es) 2020-11-17
AU2017299779B2 (en) 2021-12-02
AU2017299779A1 (en) 2019-01-31
PT3488007T (pt) 2024-03-14
JP2019524101A (ja) 2019-09-05
CN109790549A (zh) 2019-05-21
US20190284576A1 (en) 2019-09-19
ES2972859T3 (es) 2024-06-17
DK3488007T3 (da) 2024-02-19
KR20190045174A (ko) 2019-05-02
KR20220162834A (ko) 2022-12-08
SG11201900366QA (en) 2019-02-27
FI3488007T3 (fi) 2024-03-19

Similar Documents

Publication Publication Date Title
MX2019000882A (es) Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
GB2573062A (en) AAV delivery of nucleobase editors
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
PH12019500316A1 (en) Methods for detecting aav
CO2017011344A2 (es) Producción de vectores adeno-asociados de gran tamaño
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
EA201892648A1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
AU2017261249A1 (en) Adeno-associated virus polynucleotides, polypeptides and virions
MX2016010649A (es) Vector de virus adeno-asociado.
BR112018071180A2 (pt) métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
MX2018003702A (es) Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden.
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
PH12018502104A1 (en) Column-based fully scalable raav manufacturing process
NZ758023A (en) Methods of predicting ancestral virus sequences and uses thereof
CL2016002333A1 (es) Terapia genica para la retinitis pigmentaria.
MY173638A (en) Parainfluenza virus 5 based vaccines
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
MX2019007924A (es) Vacunas contra la influenza.
SA518391822B1 (ar) التحكم في عمود استخلاص
MY188494A (en) High-growth enterovirus 71 strains and vaccines
EA202191919A1 (ru) Неоантигены предстательной железы и их применение
MA41387A1 (fr) Production de vecteurs adéno-associés surdimensionnés
RU2014107103A (ru) Способ обогащения бериллиевой руды